Electrocore Llc (ECOR)
NASDAQ:ECOR
Want to see ECOR full AI Analyst Report?
ECOR Stock Chart & Stats
$6.50
$0.45(2.64%)
At close: 4:00 PM EST
$6.50
$0.45(2.64%)
Day’s Range― - ―
52-Week Range$4.16 - $10.50
Previous CloseN/A
Volume24.66K
Average Volume (3M)33.66K
Market Cap
$69.27M
Enterprise Value$76.76M
Total Cash (Recent Filing)$8.83M
Total Debt (Recent Filing)$9.48M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 12, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding8,295,707
10 Day Avg. Volume29,982
30 Day Avg. Volume33,656
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)-22.29
Price to Sales (P/S)1.19
P/FCF Ratio-4.62
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit2.52
Enterprise Value/Ebitda-5.78
Forecast
1Y Price Target
$16.62Price Target Upside155.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.52
Revenue Forecast (FY)$41.92M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & High Gross MarginsSustained revenue growth combined with mid‑80s gross margins indicates strong unit economics and product pricing power. High gross margins create durable operating leverage potential: as sales scale further, incremental revenue can flow quickly to improving EBITDA if SG&A growth moderates.
VA / Federal Channel TractionMeaningful and growing VA adoption provides a reimbursement‑driven, sticky revenue base less tied to consumer cycles. Federal channel success (VA/DoD) supports repeatable, contractable demand and a foundation for scaling commercial penetration over the coming quarters.
Commercial Leadership & R&D CatalystsExperienced commercial leadership plus a progressing clinical program and Breakthrough Device status for PTSD create structural advantages: better federal commercialization execution, stronger clinical evidence, and a clearer regulatory pathway that can unlock procurement and reimbursement opportunities.
Bears Say
Negative Cash Flow / Cash BurnConsistent negative OCF and FCF mean the business relies on external capital to fund operations. Over a 2–6 month horizon this raises financing and timing risk, constrains strategic optionality, and can force dilution or cutbacks if capital markets tighten.
Weakened Balance Sheet / Negative EquityNegative shareholders’ equity and shrinking asset base materially reduce financial flexibility. This structural balance‑sheet weakness elevates refinancing and dilution risk, and can limit the company’s ability to invest in commercial expansion or absorb operational shocks.
Ongoing Operating Losses & Elevated SG&APersistent GAAP losses and a high SG&A base constrain the path to sustained profitability. Even with margin expansion, structural operating expense levels and legal/IP costs mean revenues must grow considerably and consistently to convert strong gross margins into positive net results.
Electrocore News
ECOR FAQ
What was Electrocore Llc’s price range in the past 12 months?
Electrocore Llc lowest stock price was $4.16 and its highest was $10.49 in the past 12 months.
What is Electrocore Llc’s market cap?
Electrocore Llc’s market cap is $69.27M.
When is Electrocore Llc’s upcoming earnings report date?
Electrocore Llc’s upcoming earnings report date is Aug 12, 2026 which is in 48 days.
How were Electrocore Llc’s earnings last quarter?
Electrocore Llc released its earnings results on May 06, 2026. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.612 by $0.022.
Is Electrocore Llc overvalued?
According to Wall Street analysts Electrocore Llc’s price is currently Undervalued.
Does Electrocore Llc pay dividends?
Electrocore Llc does not currently pay dividends.
What is Electrocore Llc’s EPS estimate?
Electrocore Llc’s EPS estimate is -0.41.
How many shares outstanding does Electrocore Llc have?
Electrocore Llc has 8,295,707 shares outstanding.
What happened to Electrocore Llc’s price movement after its last earnings report?
Electrocore Llc reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.612. Following the earnings report the stock price went down -5.856%.
Which hedge fund is a major shareholder of Electrocore Llc?
Currently, no hedge funds are holding shares in ECOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electrocore Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.62 (155.64% Upside)
$16.62 (155.64% Upside)
Insider Transactions
Sold Shares
Worth $660.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.72%
12-Months-Change
Fundamentals
Return on Equity
836.32%
Trailing 12-Months
Asset Growth
-3.48%
Trailing 12-Months
Company Description
Electrocore Llc
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
ECOR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong quarter of execution: record revenue, significant YoY growth, higher gross margins (87%), and meaningful improvement in adjusted EBITDA loss, all while reaffirming full-year guidance. Management also highlighted multiple catalysts (VA and DoD expansion, TruVega international launch, Quell OTC relaunch, R&D/clinical progress including PTSD work) and added experienced commercial leadership. Key risks discussed include a decrease in cash balances, Q1 seasonal cash burn and near-term capital timing, ongoing GAAP losses driven by nonrecurring charges, concentrated product penetration in the VA (only ~2.5%), and historically variable TACSTIM revenue. On balance, the positives around accelerating revenue, margin expansion, improving adjusted EBITDA, product and channel momentum, and clear operational priorities outweigh the near-term financial and execution risks presented on the call.View all ECOR earnings summariesECOR Stock 12 Month Forecast
Average Price Target
$16.62
▲(155.64% Upside)
Technical Analysis
Myomo
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Ownership Overview
13.80% Insiders
3.15% Mutual Funds
1.77% Other Institutional Investors
78.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---